This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Phase 3, Randomized, Double-Blind, Controlled St...
Clinical trial

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination with Ribavirin, in the Treatment of Na�ve Genotype 2

Read time: 1 mins
Last updated:29th Aug 2012
The primary objective is to evaluate, in treatment-naive subjects with chronic HCV GT-2 or -3 infection: � SVR12 following 24 weeks of treatment with Lambda/RBV and the SVR12 following 24 weeks of treatment with alfa-2a/RBV � SVR12 following 12 weeks of treatment with Lambda/RBV/DCV and the SVR12 following 24 weeks of treatment with alfa-2a/RBV
Category Value
Study start date 2012-08-29

View full details